Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBIT Margin (2016 - 2025)

Utah Medical Products has reported EBIT Margin over the past 16 years, most recently at 71.69% for Q4 2025.

  • Quarterly results put EBIT Margin at 71.69% for Q4 2025, down 10369.0% from a year ago — trailing twelve months through Dec 2025 was 6.43% (down 2681.0% YoY), and the annual figure for FY2025 was 6.43%, down 40.0%.
  • EBIT Margin for Q4 2025 was 71.69% at Utah Medical Products, down from 26.61% in the prior quarter.
  • Over the last five years, EBIT Margin for UTMD hit a ceiling of 40.55% in Q3 2021 and a floor of 85.03% in Q4 2023.
  • Median EBIT Margin over the past 5 years was 34.32% (2023), compared with a mean of 23.68%.
  • Biggest five-year swings in EBIT Margin: tumbled -12238bps in 2023 and later surged 11703bps in 2024.
  • Utah Medical Products' EBIT Margin stood at 39.72% in 2021, then decreased by -6bps to 37.35% in 2022, then crashed by -328bps to 85.03% in 2023, then skyrocketed by 138bps to 32.0% in 2024, then crashed by -324bps to 71.69% in 2025.
  • The last three reported values for EBIT Margin were 71.69% (Q4 2025), 26.61% (Q3 2025), and 32.11% (Q2 2025) per Business Quant data.